Phase 3 LANTERN study reduces 30-day SSI risk by 40.5% for OBI
The LANTERN Phase 3 study met its primary endpoint, showing a 40.5% reduction in 30-day surgical site infection risk with nasal photodisinfection plus standard care. Safety was favorable, with only mild, transient adverse events, supported by both Bayesian and frequentist analyses.